Luiz Belardinelli works in Electrophysiology affiliated with Acorda Therapeutics (United States).
Luiz Belardinelli serves as the Chief Medical Officer at InCarda Therapeutics. He previously held senior positions at Gilead Sciences and CV Therapeutics, contributing to the development of cardiovascular drugs such as Ranexa and Lexiscan. His research focuses on cardiac electrophysiology and pharmacology.
539 pubs · 26,484 cites · h-index 87
MD
Medical Catholic School of Porto Alegre
1975
InCarda Therapeutics
2016 - Present
Gilead Sciences
2009 - 2015
CV Therapeutics
1999 - 2009
University of Florida
1988 - 1999
University of Virginia
1980 - 1988